AnazaoHealth lists NAD+ in several forms, including preserved and preservative-free injectable preparations, sublingual products, and topical creams. Its IV and injection catalog separates office-use and patient-specific categories. That makes the exact product and dispensing pathway important when the pharmacy’s name appears in a clinic or telehealth offer.
We reviewed the public mental-clarity and IV catalogs on September 19, 2026. We did not order medication or verify a particular clinic’s supply arrangement. This review explains the catalog distinctions and the information a patient should request from the clinician and pharmacy responsible for the actual prescription.
Ask which AnazaoHealth preparation and dispensing pathway apply to your care. Its broad catalog does not make different vial formats or routes interchangeable.
More than one injectable preparation is listed
The mental-clarity catalog identifies preserved multi-dose and preservative-free single-dose NAD+ injections. Those labels describe different product formats. They do not tell a reader which preparation is appropriate, how it should be handled, or how long any particular opened container remains usable.
Ask the pharmacist to explain the exact preparation, ingredients, container type, and label. If you have an allergy or sensitivity, make sure it is considered in that discussion. Our label-reading guide explains why a pharmacy name and an NAD+ label alone are not enough to understand a prescription.
The office-use and patient-specific sections are different
AnazaoHealth’s IV and injection catalog places NAD+ entries in sections for 503B office-use preparations and 503A patient-specific preparations. The existence of both categories does not mean every item follows the same dispensing process or that a patient can order an office-use product as a retail kit.
Ask the clinician which pathway and facility apply to the medication used in your care. The compounding pharmacy guide explains why product approval, pharmacy licensing, and outsourcing-facility status should not be conflated. A category heading is useful context, not a substitute for identifying the actual preparation.
Other routes belong in separate comparisons
The catalog also lists sublingual NAD+ products with niacin and several topical creams. These are different formulations from the injectable offerings. Their presence in the same wellness category does not establish equal effects, equivalent quantities, or a reason to substitute one product for another without clinical review.
If the main goal is avoiding needles, ask the prescriber about the actual alternatives and their evidence. Our route comparison guide explains the broader issue of comparing delivery methods. A product family can offer choices while still leaving important questions about each individual preparation unanswered.
What the public catalog does not price
The reviewed pages direct readers to the company for ordering and additional information rather than providing a complete patient treatment total. A clinic may charge for evaluation, administration, and monitoring, while an online service may charge for prescribing and delivery. Those service costs cannot be inferred from a supplier catalog.
Use the NAD+ cost guide to compare the whole care arrangement. Ask who collects payment, whether supplies and shipping are included, and what follow-up costs. A low medication-only quote can be misleading if it omits the services necessary to receive or use the prescribed preparation.
Confirm handling and clinical expectations separately
The catalog marks the injection entries for refrigerated shipment. Have the pharmacy explain the storage instructions and labeled usable period for the actual product, including what to do after a delay or temperature concern. Do not assign one handling rule to every formulation based on a shared ingredient name.
Separately, discuss what benefit the clinician expects and what evidence supports that expectation. The NAD+ evidence review explains why a supplier’s range of preparations does not establish clinical superiority. A medical goal and a reassessment plan should be clear before a recurring order or clinic package begins.
How AnazaoHealth fits with other pharmacy reviews
Compare Belmar Pharma Solutions for another catalog spanning several routes, Wells Pharmacy Network for a lyophilized vial, and Hallandale Pharmacy for a premixed listing. These reviews help identify questions about different preparations rather than rank pharmacies by unsupported treatment outcomes.
Our CoreAge Rx review covers the featured commercial partner at the service level. This supplier review does not establish which online brands use AnazaoHealth for any individual order. The practical value is knowing what to ask when that pharmacy and a specific formulation are named in your care plan.
Follow the source
References & further reading
- AnazaoHealth — NAD+ formulations
Checked September 19, 2026. Preserved and preservative-free injectable formats, plus distinct non-injection preparations.
- AnazaoHealth — IV and injection catalog
Checked September 19, 2026. Distinguishes 503B office-use and 503A patient-specific categories; not FDA product approval.
- FDA — compounding questions and answers
Compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality.
- FDA — ingredients suitable for sterile compounding
Reports NAD+ injectable adverse events and ingredient-quality concerns.
- Grant et al. (2019) — human NAD+ infusion pilot
Small IV metabolism study; does not establish benefits of home injections.